Mainstay Medical launches limited commercial release of neurostimulation system in US
Click Here to Manage Email Alerts
Dublin-based Mainstay Medical announced the launch of its product ReActiv8 in the U.S. in limited commercial quantities, according to a press release.
ReActiv8 is a neurostimulation implant system that treats intractable chronic low back pain in patients who have not improved with physical therapy or pain medications and are not candidates for spine surgery, according to the release. It will be available to U.S. patients exclusively through system-certified physicians starting in summer 2021.
“We are launching in a limited fashion to ensure we provide proper education to physicians and assist them in selecting the appropriate patients,” Jason Hannon, CEO of Mainstay Medical, said in the release. “We look forward to expanding the availability of ReActiv8 across the U.S. over the coming months and building on the momentum we have gained in Europe and Australia to continue to improve the quality of patients’ lives.”
In conjunction with the limited commercial launch, Mainstay Medical established a new website to educate physicians and patients on ReActiv8, as well as to provide tools, training and guidance on the system.
“We expect that these resources will facilitate the identification of strong candidates for ReActiv8 and drive compelling patient outcomes,” Hannon said.
Read more about
Click Here to Manage Email Alerts